Industry news
-
Scientists make long-lasting but controversial human-monkey embryos for medical research
16 April 2021
Scientists use different models to study human disease when it would be too early or ethically problematic to run experiments in humans. Those models aim to mimic human biology as closely as possible to allow more accurate results.
-
Biologics CDMO market to double in value by 2026, suggests report
16 April 2021
Research suggests the increasing R&D investment in and adoption of biologics will drive growth in the global biologics contract development and manufacturing organisation (CDMO) market.
-
15 April 2021
By combining artificial intelligence and an extensive atlas of protein biology, Cyclica is taking new approaches to searching for old drugs that could fight COVID-19—and, now, it’s helped find what could become a first-in-class candidate.
-
Pharma's pandemic reputation gains score a 'most-improved' medal in annual ranking
15 April 2021
Pharma continues to shine under the pandemic spotlight. The Global RepTrak 100 is the latest to mark the industry's image improvements—noted as the poll’s biggest year-over-year gain among all its industry categories.
-
How to accelerate oncology clinical trials through site relationships and patient insights
14 April 2021
All stakeholders benefit when patients and their insights are at the heart of every aspect of clinical development. However, putting that approach into practice requires knowledge of the unique needs of cancer patients. Parexel has accrued that knowledge through ongoing initiatives that have strengthened its relationships with the sites, investigators and research nurses who know patients best.
-
Look before you leap: How a joined-up development strategy pays off for early-stage biotechs
14 April 2021
Developing new therapies is an enormously exciting endeavor—after all, what can be more rewarding than developing an important new therapy for patients? But that excitement and optimism can sometimes lead biotechs to launch into a clinical program without having the opportunity to properly dissect future regulatory and payer challenges, and that can undermine value.
-
The top 10 medtech M&A deals of 2020
13 April 2021
Over the past year, there were more than enough times when it felt like the world had stopped turning. Outside of unceasing demand for protective equipment, ventilator hardware and diagnostic tests, the COVID-19 pandemic brought many medical procedures to a standstill, which in turn halted the circulation of devices throughout the industry and slowed the rate of medtech mergers and acquisitions to a crawl.
-
Did pharma overshoot digital sales rep calls? Study charts decline in effectiveness
13 April 2021
A year after the pandemic forced pharma reps to switch from in-person to digital sales calls, most visits are still virtual—and the industry is seeing mixed results.
-
12 April 2021
As a Democrat-led U.S. government is looking to once again up the pressure on drug pricing, a new report has shown biopharmas are in fact reinvesting more and more sales revenue into R&D.
-
12 April 2021
The gene editing system CRISPR-Cas9 makes breaks in DNA strands that are repaired by cells—a process that can be hard to control, resulting in unwanted genetic changes. Researchers at the Massachusetts Institute of Technology and the University of California, San Francisco (UCSF) designed an alternative technology that changes gene expression without damaging DNA, and they believe it could be useful for both research and drug development.
